Drug Search Results
More Filters [+]

Anacetrapib

Alternative Names: anacetrapib, mk0859, mk-0859, mk 0859
Latest Update: 2024-04-22
Latest Update Note: PubMed Publication

Product Description

Anacetrapib is a potent inhibitor of CETP that increases circulating levels of high-density lipoprotein (HDL) cholesterol and lowers the levels of non-HDL cholesterol [particularly low-density lipoprotein (LDL) cholesterol]. (Sourced from: https://doi.org/10.1093/eurheartj/ehab863)

Mechanisms of Action: CETP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Anacetrapib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Coronary Artery Disease|Myocardial Ischemia|Hypercholesterolemia|Dyslipidemia|Hyperlipoproteinemia Type II|Hyperlipidemia|Hyperlipoproteinemias|Myocardial Infarction|Coronary Disease|Atherosclerosis

Phase 2: Hyperlipoproteinemia Type V|Hyperlipidemia|Hypercholesterolemia|Dyslipidemia

Phase 1: Other|Dyslipidemia|Kidney Diseases|Liver Failure|Hepatic Insufficiency|Hypercholesterolemia|Hyperlipidemia|Hyperlipoproteinemias

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Study of Anaceptrapib in Heterozygous Familial Hypercholesterolemia

P3

Completed

Hypercholesterolemia

2018-11-13

REVEAL-Vasc

N/A

Completed

Atherosclerosis

2018-05-01

REVEAL

P3

Active, not recruiting

Atherosclerosis

2017-01-31

REVEAL Version 1.0

P3

Unknown status

Myocardial Infarction|Coronary Disease

2016-09-25

Recent News Events